duration of onset of bacteremia after UCBT with a median of 15 days and the duration of 3-34 days, compared with after UBMT. Graft-vs-host disease of grade II, III or IV occurred in 2 of 10 patients who survived more than 100 days after UCBT and in 15 of 40 after UBMT. The TRM and EFS at 2 years post-transplant in patients at an early disease stage were 12.5 % and 75.0 % after UCBT and 6.5% and 68.7% after UBMT. Conclusion: UCB transplantation in adults is associated with delayed neutrophil

more »

... very and longer duration of bacteremia at early time points after transplantation. The TRM (12.5%) and EFS (75.0%) at 2 years after transplantation were similar to our experience of UBMT. Thus, parallel to the search for a matched unrelated donor, searching for an adequate UCB unit should be initiated. The published experience of reduced-intensity allogeneic stem cell transplantation (ASCT) for acute lymphoblastic leukemia (ALL) remains limited. Some studies have been shown that the graft-versus-leukemia effect is not powerful enough to make this conditioning regimen useful in ALL. On the other hand, indolent lymphoproliferative disorders (ILD) has been associated, in some studies, with high mortality when reduced-intensity ASCT was used as a piece of a treatment. We evaluated the outcome and survival of both ALL and ILD patients who received a reducedintensity SCT in our hospital. A total of 20 high risk patients in ALL group and 10 patients in ILD group (3 with chronic lymphocytic leukemia and 7 with indolent non Hodgkin lymphoma) were included. The median age for both groups was 19 years and 43 years respectively. All patients received cyclophosphamide IV 300 mg/m 2 and fludarabine 30 mg/m 2 for 3 days (Ϫ6, Ϫ5, Ϫ4) and cyclophosphamide IV 50 mg/kg/day or busulphan 4 mg/kg/day for 2 days (Ϫ3, Ϫ2) as conditioning regimen. In 20 patients (67%) it was administrated as ambulatory setting. Daily oral cyclosporine and methotrexate (days ϩ1, ϩ3, ϩ5) were delivery as prophylactic GVHD. The median CD34ϩ cell dose infused was 5.37 ϫ 10 6 in ALL and 5.2 ϫ 10 6 in ILD group. Neutrophil recovery to 0.5 ϫ 10 9 /l was observed at day ϩ13 (median) in both groups. Acute and chronic GVHD was developed more frequently in ILD group than in ALL group (40% vs. 25%). Relapse was higher in ALL group (65%) than in ILD group (10%) and this complication was the principal cause of death in both groups (50% vs. 10%). In all, 19 patients died, 16 (80%) patients in ALL group and 3 (30%) patients in ILD group. We conclude that reduced-intensity ASCT in high-risk ALL patients could not be the best choice for treatment. We believe that this conditioning regimen can be used successfully in treatment of patients with ILD, however, in ALL more studies and new ideas are needed.